论文部分内容阅读
老年患者因基础代谢下降、重要脏器的功能衰退、肾小球滤过率降低、骨髓造血功能降低、心脏储备功能降低等改变将导致其对各种治疗的耐受性相对降低而治疗毒副反应发生增加。老年NSCLC患者治疗的循证医学证据来源于晚期肺癌的临床研究,同时根据其自身状况,制定合理的治疗方案,以达到最佳的治疗效果,包括最佳支持治疗,含第三代化疗药物的化疗,非铂类为主的联合化疗,铂类为主的联合化疗以及靶向治疗等新型生物制剂。
Elderly patients due to decreased basal metabolism, functional decline of important organs, glomerular filtration rate decreased bone marrow hematopoietic function decreased cardiac reserve function changes will lead to a variety of its treatment is relatively reduced tolerance and the treatment of toxic and toxic The reaction has increased. Evidence-based medical evidence of treatment for elderly patients with NSCLC comes from the clinical study of advanced lung cancer, and according to its own condition, to develop a reasonable treatment plan to achieve the best therapeutic effect, including the best supportive treatment, including third-generation chemotherapy drugs Chemotherapy, non-platinum-based combination chemotherapy, platinum-based combination chemotherapy and targeted therapies and other new biological agents.